All Online

1 - 11 of 11 results

Refine

Active filters

GLP-1 Receptor Agonists
1 CME CREDIT

This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines.


1 CME CREDIT

This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on February 7, 2020, and they are subject to change as new information is published.


Woman looking at insulin pen while doctor looks at her
1 CME CREDIT

Updates from American Diabetes Association 2021

1.00 CME/MOC
1.00 AANP | 1.00 Pharmacology

This session will cover some new data regarding treatment of type 2 diabetes: the GRADE study, SURPASS phase 3 program, the STEP program for treatment of obesity. It will also provide an update on studies using SGLT2 inhibitors and GLP 1 receptor agonists in people with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.


Physician attending to patient

Maximum 50 words to introduce the activity The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs and review guideline updates that support use of GLP-1 RA early in the treatment paradigm.


Senior male puncturing finger for test
1 CME CREDIT

The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs.


Coffee with Chopra: Episode 1
0.5 CME CREDIT

Advances in Diabetes and Reflections on Care

Episode 1: Coffee with Chopra

0.50 CME

Join Dr. Sanjiv Chopra, hepatologist, author, speaker, and thought leader as he interviews his guest, Dr. Martin Abrahamson, endocrinologist and associate professor at Harvard Medical School as they discuss major advances in diabetes as well as the promise of stem cell treatment, diet and weight loss in patients with diabetes, and advances in continuous glucose monitoring. The pair will end their conversation discussing what they have learned from patients over the years.


Nurse explaining the use of diabetic equipment to a patient
0.5 CME CREDIT

Time to meet your new patient! In this interactive activity, you will be guided through the case of a patient with type 2 diabetes at high-risk for atherosclerotic cardiovascular disease (ASCVD) via a series of questions and complementary videos. Questions will test your strengths and weaknesses around diabetes management, with some questions and feedback tailored directly to your management choices. After each question, you will be presented with learning moments designed to help increase your confidence managing patients with type 2 diabetes and reducing cardiovascular risk.


0.75 CME CREDIT

Obesity and Diabetes Update

0.75 CME/MOC
0.75 AANP | 0.28 Pharmacology

Dr. Martin Abrahamson will review the pathophysiology of type 2 diabetes, discuss non-insulin treatments, and explore the most recent guidelines and recommendations for advancing treatment in people with type 2 diabetes to achieve glycemic goals. Dr. Frank Domino will then review a basic framework for counseling patients on weight loss, including a discussion of best evidence on diet, exercise, and appropriate use of medication. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 12/03/2020, and they are subject to change as new information is published.


smiling nutritionist showing diet plan
1 CME CREDIT

Given that 9 out of 10 people with diabetes also suffer from overweight or obesity, it is important for PCPs to take a holistic approach to treatment rather than solely a glucocentric approach. This activity helps you understand the benefits of weight loss as a key therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM) and the importance of early treatment intensification to improve long-term outcomes. You’ll also walk away from this session with a firm grasp of the role incretins play in the pathophysiology of T2DM, obesity, and other metabolic conditions and the latest clinical trial evidence behind incretin-based agents.


Physician talking with female patient
0.28 CME CREDIT

Hitting Diabetes Head-on: Improving Outcomes and Reducing Therapeutic Inertia With GLP-1 Receptor Agonists: AdaptED Module 1

An Interactive Learning ExperienceThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

0.25 CME/MOC
0.28 AANP | 0.28 Pharmacology

The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs and review guideline updates that support use of GLP-1 RA early in the treatment paradigm. Learners will have the opportunity to evaluate their knowledge through multiple-choice and matching questions and case-based application.


Doctor in protective shield mask talks to obese black woman
0.28 CME CREDIT

Hitting Diabetes Head-on: Improving Outcomes and Reducing Therapeutic Inertia With GLP-1 Receptor Agonists: AdaptED Module 2

An Interactive Learning Experience This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

0.25 CME/MOC
0.28 AANP | 0.28 Pharmacology

The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs and review guideline updates that support use of GLP-1 RA early in the treatment paradigm. Learners will have the opportunity to evaluate their knowledge through multiple-choice and matching questions and case-based application.